Navigation Links
Health Canada approves cold and flu medicine

Health Canada, the Canadian government regulatory agency, has approved wide-ranging new health claims for COLD-fX®, the most popular cold/flu remedy in Canada. After an extensive review, the Natural Health Products Directorate (NHPD) ?a division of Health Canada responsible for evaluating the safety, efficacy and quality of natural health products (NHPs) ?has issued COLD-fX with a much sought after license to sell to the public with specific science backed claims.

The comprehensive treatment claim for COLD-fX® approved by Health Canada states that the product “helps reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system.? Comprehensive therapeutic claims require support by the highest level of scientific evidence: randomized, double-blind, placebo-controlled clinical trials.

“This is our strongest point of medical recognition to date, and coming from the government authority whose responsibility it is to help Canadians maintain and improve their health, this approval should give great confidence to consumers,?said Dr. Jacqueline Shan, co-founder of CV Technologies, a University of Alberta spinoff company that developed COLD-fX.

Shan, who is also president, CEO and Chief Scientific Officer of CV Technologies added, “There are two novel therapeutic aspects to COLD-fX. First, COLD-fX is one of the very few medicines ?drugs or natural health products ?that Health Canada has approved for daily use as a preventative medicine. Second, COLD-fX can be taken to provide symptom relief for colds and flu."

Shan added that Health Canada reviewed all of CV Technologies published and unpublished data on COLD-fx before approving the claims.

The NHPD issues product licenses in several categories. Because COLD-fX® is a unique patented product, it was issued an NPN in the non-traditional category, which requires the highest level of scientific evidence. In contrast, claims with the term “tra
'"/>

Source:University of Alberta


Page: 1 2

Related biology news :

1. BioMed Central welcomes the new National Institutes of Health public access policy
2. OneWorld Health drug receives Orphan designation from U.S. and European regulatory agencies
3. Health costs soar as 60 million Americans classed as obese
4. Going To Extremes To Improve Human Health
5. Patient-choice C-section rate rises 36%: HealthGrades study
6. Grand Challenges in Global Health initiative funds Yale project
7. Health benefits of a Christmas brandy
8. Health of coral reefs detected from orbit
9. Health of Acehnese reefs in the wake of the tsunami shows human impacts more harmful
10. Healthy coral reefs of Madagascar resisting damage from climate change
11. Mailman School of Public Health researchers report blood DNA can be early predictor of liver cancer
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Health Canada approves cold and flu medicine

(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications Corp. ... global provider of Software Defined Network Architecture (ET Software ... total revenue of approximately $20.4 million for the year ... $19.5 million for the year ended December 31, 2013. ... the Company had completed its multi-year transition away from ...
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... by 2100 and potentially more than 8C by 2200 if ... published in Nature . Scientists found global climate is ... The research also appears to solve one of the great ... whether this will have a positive or negative effect on ...
... for artery in vascular transplantation, but it remains unclear whether ... A recent study reported in the Neural Regeneration Research ... decrease at 7 200 seconds was similar between the middle ... stress of 18.7 kPa or 22.5 kPa. However, the strain ...
... trees lose ground to deforestation and urban sprawl, one development ... winter cold snaps have enabled them to conquer new territory ... 28 years of satellite data from the Smithsonian Environmental Research ... the Proceedings of the National Academy of Sciences . ...
Cached Biology News:Cloud mystery solved: Global temperatures to rise at least 4C by 2100 2Climate change spurs tropical mangroves to expand in the north 2
(Date:4/30/2015)... 30, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) reported ... 2015 were $4.4 million, compared to $8.0 million during the ... first quarter was $8.9 million, or $0.23 per basic and ... the same period in 2014, of $8.7 million, or $0.27 ... 2015, cash, cash equivalents and investments totaled $117.5 million. ...
(Date:4/30/2015)... , April 30, 2015 Oxford Finance ... debt to life sciences and healthcare services companies, today ... term loan agreement with Celula, Inc., a diagnostic testing ... diseases, enabling better patient care and improved outcomes.  Proceeds ... development and expand the commercialization of its products in ...
(Date:4/30/2015)... , April 30, 2015  The Paul G. Allen ... Investigator (ADI) grants to six groups of researchers with ... challenging roadblocks in neuroscience: growing mature human brain cells ... total of $7.5 million over three years.  ... their research is especially significant because the field of ...
(Date:4/30/2015)... , April 30, 2015 - ... Global Biotechnology Company   Shire (LSE: ... the three months to March 31, 2015. ... $1,423 million +9% +13% Total revenues $1,488 million +11% ... US GAAP operating income from continuing operations $475 million ...
Breaking Biology Technology:Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Oxford Finance Provides $10 Million Debt Financing to Celula 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 2Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 3Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 4Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 6Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 7Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 8Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 9Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 10Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 11Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 12Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 13Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 14Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 15Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 16Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 17Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 18Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 19Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 20Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 21Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 22Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 23Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 24
... HIV Vaccine ... ... (Nasdaq: MGRM ) today announced that company,researchers have co-authored with ... the Keystone HIV,Vaccines: Progress and Prospects Symposium in Banff, Alberta., ...
... -- Third Sequential Profitable Quarter -- -- ... ET --, BEIJING, March 31 /Xinhua-PRNewswire/ -- Sinovac Biotech ... announced unaudited,financial results for the three months and twelve months ... full year 2007 sales of $33.5 million, up 118% year-over-year ...
... CHICAGO, March 29 Boston,Scientific Corporation (NYSE: ... two-year data from more than 7,000 patients in ... to evaluate the safety performance of the,TAXUS(R) Express2(TM) ... practice. Outcomes through two years in the simple-,use ...
Cached Biology Technology:Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program 2Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program 3Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program 4Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program 5Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 2Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 3Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 4Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 5Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 6Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 7Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 8Real-World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS(R) Express(TM) Stent 2Real-World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS(R) Express(TM) Stent 3Real-World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS(R) Express(TM) Stent 4
2.0 GHz Compaq Computer with 512 MB RAM, 32 MB AGP Graphics Card, 40 GB Hard Drive, 1 Serial Port & Open PCI Slot, Windows 2000 OS, MS Office, CD Read/Writer and 18 Flat Panel Monitor...
Quartz-Halogen, 100 W, High Intensity...
The product contains 10 ml Dynabeads Epoxy (4.5 m). Supplied at 4 x 10 8 beads/ml...
Porcine parvovirus and mycoplasma tested. Contains 0.5 g/L of trypsin (1:250) and 0.2 g/L of EDTA4Na in Hanks' Balanced Salt Solution without CaCl2 MgCl2 6H2O and MgSO4 7H2O. Contains phenol red....
Biology Products: